| Abstract: | The development of farnesyltransferase inhibitors (FTIs) was conceived of as a rational approach to the design of new cancer chemotherapeutics and the first examples of this class are currently being evaluated in Phase II and Phase III clinical trials. This review summarises the scientific and patent literature published in the 14 month period from March 1999, since the previous review [1]. In addition to a survey of novel prenyl transferase inhibitors, recent clinical data and developments in related biochemistry and biology are described. |
